

## ECUADOR, 5 registries (1993-2013)

	Number of cases							Percentage				Incidence rates per million person-years								MV % 0-19	DCO % 0-19		
	Age group							0-14		0-19		Age-specific					Cumulative						
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	ASR	0-19			0-14	0-19
<b>I LEUKAEMIA</b>	70	531	410	307	304	<b>1318</b>	<b>1622</b>	43.7	100.0	39.1	100.0	53.4	90.3	56.0	41.6	41.3	<b>62.5</b>	<b>57.7</b>	905	1112	96.0	2.7	
a. Lymphoid	33	433	326	217	183	<b>1009</b>	<b>1192</b>	33.4	76.6	28.8	73.5	25.2	73.6	44.5	29.4	24.8	<b>48.0</b>	<b>42.8</b>	693	818	100.0	0.0	
b. Acute myeloid	16	55	50	61	72	<b>182</b>	<b>254</b>	6.0	13.8	6.1	15.7	12.2	9.4	6.8	8.3	9.8	<b>8.4</b>	<b>8.7</b>	125	174	100.0	0.0	
c. CMD	6	9	5	6	26	<b>26</b>	<b>52</b>	0.9	2.0	1.3	3.2	4.6	1.5	0.7	0.8	3.5	<b>1.3</b>	<b>1.8</b>	18	36	100.0	0.0	
d. MDS & other	0	2	1	0	2	<b>3</b>	<b>5</b>	0.1	0.2	0.1	0.3	-	0.3	0.1	-	0.3	<b>0.2</b>	<b>0.2</b>	2	3	100.0	0.0	
e. Unspecified	15	32	28	23	21	<b>98</b>	<b>119</b>	3.2	7.4	2.9	7.3	11.4	5.4	3.8	3.1	2.8	<b>4.7</b>	<b>4.3</b>	67	82	45.4	37.0	
<b>II LYMPHOMA &amp; RELATED</b>	14	113	155	135	189	<b>417</b>	<b>606</b>	13.8	100.0	14.6	100.0	10.7	19.2	21.2	18.3	25.6	<b>19.0</b>	<b>20.5</b>	285	414	95.7	1.2	
a. Hodgkin	1	25	53	50	66	<b>129</b>	<b>195</b>	4.3	30.9	4.7	32.2	0.8	4.3	7.2	6.8	9.0	<b>5.7</b>	<b>6.4</b>	88	133	99.5	0.0	
b. Non-Hodgkin except BL	0	48	71	53	99	<b>172</b>	<b>271</b>	5.7	41.2	6.5	44.7	-	8.2	9.7	7.2	13.4	<b>7.8</b>	<b>9.1</b>	118	185	100.0	0.0	
c. Burkitt (BL)	1	13	15	5	6	<b>34</b>	<b>40</b>	1.1	8.2	1.0	6.6	0.8	2.2	2.0	0.7	0.8	<b>1.6</b>	<b>1.4</b>	23	27	100.0	0.0	
d. Lymphoreticular	10	12	4	6	1	<b>32</b>	<b>33</b>	1.1	7.7	0.8	5.4	7.6	2.0	0.5	0.8	0.1	<b>1.6</b>	<b>1.3</b>	22	23	100.0	0.0	
e. Unspecified	2	15	12	21	17	<b>50</b>	<b>67</b>	1.7	12.0	1.6	11.1	1.5	2.6	1.6	2.8	2.3	<b>2.3</b>	<b>2.3</b>	34	46	62.7	10.4	
<b>III CNS NEOPLASMS †</b>	19	124	151	91	93	<b>385</b>	<b>478</b>	12.8	100.0	11.5	100.0	14.5	21.1	20.6	12.3	12.6	<b>17.9</b>	<b>16.7</b>	264	327	80.3	3.3	
a. Ependymoma	4	9	15	5	1	<b>33</b>	<b>34</b>	1.1	8.6	0.8	7.1	3.1	1.5	2.0	0.7	0.1	<b>1.6</b>	<b>1.2</b>	23	23	100.0	0.0	
b. Astrocytoma	3	43	66	34	52	<b>146</b>	<b>198</b>	4.8	37.9	4.8	41.4	2.3	7.3	9.0	4.6	7.1	<b>6.7</b>	<b>6.8</b>	100	135	93.4	0.0	
c. CNS embryonal	4	46	35	30	17	<b>115</b>	<b>132</b>	3.8	29.9	3.2	27.6	3.1	7.8	4.8	4.1	2.3	<b>5.4</b>	<b>4.7</b>	79	90	99.2	0.0	
d. Other gliomas	0	9	8	6	6	<b>23</b>	<b>29</b>	0.8	6.0	0.7	6.1	-	1.5	1.1	0.8	0.8	<b>1.1</b>	<b>1.0</b>	16	20	69.0	0.0	
e. Other specified	0	3	0	4	4	<b>7</b>	<b>11</b>	0.2	1.8	0.3	2.3	-	0.5	-	0.5	0.5	<b>0.3</b>	<b>0.4</b>	5	8	100.0	0.0	
f. Unspecified CNS	8	14	27	12	13	<b>61</b>	<b>74</b>	2.0	15.8	1.8	15.5	6.1	2.4	3.7	1.6	1.8	<b>2.8</b>	<b>2.6</b>	42	51	4.1	21.6	
<b>IV NEUROBLASTOMA</b>	8	16	7	10	3	<b>41</b>	<b>44</b>	1.4	100.0	1.1	100.0	6.1	2.7	1.0	1.4	0.4	<b>2.0</b>	<b>1.6</b>	28	30	88.6	0.0	
a. (Ganglio)neuroblastoma	7	16	7	9	2	<b>39</b>	<b>41</b>	1.3	95.1	1.0	93.2	5.3	2.7	1.0	1.2	0.3	<b>1.9</b>	<b>1.5</b>	27	28	87.8	0.0	
b. Peripheral nervous	1	0	0	1	1	<b>2</b>	<b>3</b>	0.1	4.9	0.1	6.8	0.8	-	-	0.1	0.1	<b>0.1</b>	<b>0.1</b>	1	2	100.0	0.0	
<b>V RETINOBLASTOMA</b>	28	99	8	0	0	<b>135</b>	<b>135</b>	4.5	100.0	3.3	100.0	21.4	16.8	1.1	-	-	<b>7.2</b>	<b>5.6</b>	94	94	94.8	0.0	
<b>VI RENAL TUMOURS</b>	14	80	28	5	4	<b>127</b>	<b>131</b>	4.2	100.0	3.2	100.0	10.7	13.6	3.8	0.7	0.5	<b>6.5</b>	<b>5.2</b>	88	91	83.2	3.8	
a. Nephroblastoma	11	76	26	5	1	<b>118</b>	<b>119</b>	3.9	92.9	2.9	90.8	8.4	12.9	3.5	0.7	0.1	<b>6.0</b>	<b>4.7</b>	82	82	89.9	1.7	
b. Renal carcinoma	0	0	0	0	2	<b>0</b>	<b>2</b>	-	-	0.0	1.5	-	-	-	-	0.3	-	<b>0.1</b>	-	1	1	100.0	0.0
c. Unspecified	3	4	2	0	1	<b>9</b>	<b>10</b>	0.3	7.1	0.2	7.6	2.3	0.7	0.3	-	0.1	<b>0.5</b>	<b>0.4</b>	6	7	0.0	30.0	
<b>VII HEPATIC TUMOURS</b>	15	29	11	11	9	<b>66</b>	<b>75</b>	2.2	100.0	1.8	100.0	11.4	4.9	1.5	1.5	1.2	<b>3.3</b>	<b>2.8</b>	46	52	81.3	5.3	
a. Hepatoblastoma	14	23	7	5	2	<b>49</b>	<b>51</b>	1.6	74.2	1.2	68.0	10.7	3.9	1.0	0.7	0.3	<b>2.5</b>	<b>2.0</b>	34	35	96.1	2.0	
b. Hepatic carcinoma	0	0	2	5	5	<b>7</b>	<b>12</b>	0.2	10.6	0.3	16.0	-	-	0.3	0.7	0.7	<b>0.3</b>	<b>0.4</b>	5	8	100.0	0.0	
c. Unspecified	1	6	2	1	2	<b>10</b>	<b>12</b>	0.3	15.2	0.3	16.0	0.8	1.0	0.3	0.1	0.3	<b>0.5</b>	<b>0.5</b>	7	8	0.0	25.0	
<b>VIII BONE TUMOURS</b>	0	4	36	101	94	<b>141</b>	<b>235</b>	4.7	100.0	5.7	100.0	-	0.7	4.9	13.7	12.8	<b>5.8</b>	<b>7.3</b>	96	159	94.9	0.9	
a. Osteosarcoma	0	0	26	80	66	<b>106</b>	<b>172</b>	3.5	75.2	4.1	73.2	-	-	3.5	10.8	9.0	<b>4.3</b>	<b>5.3</b>	72	117	98.8	0.0	
b. Chondrosarcoma	0	0	3	3	1	<b>6</b>	<b>7</b>	0.2	4.3	0.2	3.0	-	-	0.4	0.4	0.1	<b>0.3</b>	<b>0.2</b>	4	5	100.0	0.0	
c. Ewing & related	0	4	6	10	15	<b>20</b>	<b>35</b>	0.7	14.2	0.8	14.9	-	0.7	0.8	1.4	2.0	<b>0.9</b>	<b>1.1</b>	14	24	100.0	0.0	
d. Other specified	0	0	0	2	5	<b>2</b>	<b>7</b>	0.1	1.4	0.2	3.0	-	-	-	0.3	0.7	<b>0.1</b>	<b>0.2</b>	1	5	100.0	0.0	
e. Unspecified	0	0	1	6	7	<b>7</b>	<b>14</b>	0.2	5.0	0.3	6.0	-	-	0.1	0.8	0.9	<b>0.3</b>	<b>0.4</b>	5	9	28.6	14.3	
<b>IX SOFT TISSUE SARCOMA</b>	14	34	30	56	66	<b>134</b>	<b>200</b>	4.4	100.0	4.8	100.0	10.7	5.8	4.1	7.6	9.0	<b>6.1</b>	<b>6.7</b>	92	137	98.5	0.5	
a. Rhabdomyosarcoma	7	20	16	26	18	<b>69</b>	<b>87</b>	2.3	51.5	2.1	43.5	5.3	3.4	2.2	3.5	2.4	<b>3.2</b>	<b>3.0</b>	47	60	98.9	1.1	
b. Fibrosarcoma	3	4	3	5	13	<b>15</b>	<b>28</b>	0.5	11.2	0.7	14.0	2.3	0.7	0.4	0.7	1.8	<b>0.7</b>	<b>0.9</b>	10	19	100.0	0.0	
c. Kaposi sarcoma	0	0	0	1	1	<b>1</b>	<b>2</b>	0.0	0.7	0.0	1.0	-	-	-	0.1	0.1	<b>0.0</b>	<b>0.1</b>	1	1	100.0	0.0	
d. Other specified	2	6	7	15	22	<b>30</b>	<b>52</b>	1.0	22.4	1.3	26.0	1.5	1.0	1.0	2.0	3.0	<b>1.3</b>	<b>1.7</b>	20	35	100.0	0.0	
e. Unspecified	2	4	4	9	12	<b>19</b>	<b>31</b>	0.6	14.2	0.7	15.5	1.5	0.7	0.5	1.2	1.6	<b>0.9</b>	<b>1.0</b>	13	21	93.5	0.0	
<b>X GERM CELL TUMOURS</b>	13	37	21	41	170	<b>112</b>	<b>282</b>	3.7	100.0	6.8	100.0	9.9	6.3	2.9	5.5	23.1	<b>5.2</b>	<b>9.2</b>	77	192	95.4	0.7	
a. CNS germ cell	1	3	1	3	3	<b>8</b>	<b>11</b>	0.3	7.1	0.3	3.9	0.8	0.5	0.1	0.4	0.4	<b>0.4</b>	<b>0.4</b>	5	8	90.9	0.0	
b. Other extragonadal	2	5	2	3	13	<b>12</b>	<b>25</b>	0.4	10.7	0.6	8.9	1.5	0.9	0.3	0.4	1.8	<b>0.6</b>	<b>0.8</b>	8	17	96.0	0.0	
c. Gonadal germ cell	10	29	15	30	130	<b>84</b>	<b>214</b>	2.8	75.0	5.2	75.9	7.6	4.9	2.0	4.1	17.6	<b>3.9</b>	<b>7.0</b>	58	146	100.0	0.0	
d. Gonadal carcinoma	0	0	0	1	15	<b>1</b>	<b>16</b>	0.0	0.9	0.4	5.7	-	-	-	0.1	2.0	<b>0.0</b>	<b>0.5</b>	1	11	100.0	0.0	
e. Unspecified gonadal	0	0	3	4	9	<b>7</b>	<b>16</b>	0.2	6.3	0.4	5.7	-	-	0.4	0.5	1.2	<b>0.3</b>	<b>0.5</b>	5	11	31.3	12.5	
<b>XI CARCINOMA &amp; MELANOMA</b>	4	7	22	47	165	<b>80</b>	<b>245</b>	2.7	100.0	5.9	100.0	3.1	1.2	3.0	6.4	22.4	<b>3.4</b>	<b>7.7</b>	54	166	99.6	0.0	
a. Adrenocortical	0	0	0	0	1	<b>0</b>	<b>1</b>	-	-	0.0	0.4	-	-	-	-	0.1	-	<b>0.0</b>	-	1	1	100.0	0.0
b. Thyroid	0	0	7	22	64	<b>29</b>	<b>93</b>	1.0	36.3	2.2	38.0	-	-	1.0	3.0	8.7	<b>1.2</b>	<b>2.9</b>	20	63	100.0	0.0	
c. Nasopharyngeal	0	0	0	0	1	<b>0</b>	<b>1</b>	-	-	0.0	0.4	-	-	-	-	0.1	-	<b>0.0</b>	-	1	1	100.0	0.0
d. Melanoma	4	4	6	3	6	<b>17</b>	<b>23</b>	0.6	21.3	0.6	9.4	3.1	0.7	0.8	0.4	0.8	<b>0.8</b>	<b>0.8</b>	12	16	95.7	0.0	
e. Skin carcinoma	0	2	5	12	27	<b>19</b>	<b>46</b>	0.6	23.8	1.1	18.8	-	0.3	0.7	1.6	3.7	<b>0.8</b>	<b>1.4</b>	13	31	100.0	0.0	
f. Other & unspecified	0	1	4	10	66	<b>15</b>	<b>81</b>	0.5	18.8	2.0	33.1	-	0.2	0.5	1.4	9.0	<b>0.6</b>	<b>2.5</b>	10	55	100.0	0.0	
<b>XII OTHER &amp; UNSPECIFIED</b>	7	18	13	24	30	<b>62</b>	<b>92</b>	2.1	100.0	2.2	100.0	5.3	3.1	1.8	3.2	4.1	<b>2.9</b>	<b>3.1</b>	42	63	14.1	21.7	
a. Other specified	0	2	0	1	3	<b>3</b>	<b>6</b>	0.1	4.8	0.1	6.5	-	0.3	-	0.1	0.4	<b>0.1</b>	<b>0.2</b>	2	4	100.0	0.0	
b. Other unspecified	7	16	13	23	27	<b>59</b>	<b>86</b>	2.0	95.2	2.1	93.5	5.3	2.7	1.8	3.1	3.7	<b>2.7</b>	<b>2.9</b>	40	59	8.1	23.3	
<b>TOTAL</b>	206	1092	892	828	1127	<b>3018</b>																	

## ECUADOR, 5 registries (1993-2013)

	Males										M/F ratio		Females											
	Number of cases in age groups										0-14	0-19	Number of cases in age groups										0-14	0-19
	0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19			0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19		
<b>I LEUKAEMIA</b>	26	287	220	165	185	698	883	65.3	62.1	1.1	1.2	44	244	190	142	119	620	739	59.6	53.3				
a. Lymphoid	15	238	179	121	118	553	671	51.9	47.6	1.2	1.3	18	195	147	96	65	456	521	43.9	37.9				
b. Acute myeloid	7	32	26	35	39	100	139	9.1	9.5	1.2	1.2	9	23	24	26	33	82	115	7.7	7.9				
c. CMD	3	3	1	3	15	10	25	1.0	1.7	0.6	0.9	3	6	4	3	11	16	27	1.6	1.9				
d. MDS & other	0	1	0	0	1	1	2	0.1	0.1	0.5	0.7	0	1	1	0	1	2	3	0.2	0.2				
e. Unspecified	1	13	14	6	12	34	46	3.2	3.2	0.5	0.6	14	19	14	17	9	64	73	6.2	5.3				
<b>II LYMPHOMA &amp; RELATED</b>	5	75	105	82	115	267	382	24.1	25.8	1.8	1.7	9	38	50	53	74	150	224	13.8	15.1				
a. Hodgkin	0	17	39	32	35	88	123	7.7	8.1	2.1	1.7	1	8	14	18	31	41	72	3.7	4.7				
b. Non-Hodgkin except BL	0	29	42	31	62	102	164	9.2	10.9	1.5	1.5	0	19	29	22	37	70	107	6.4	7.2				
c. Burkitt (BL)	1	11	12	5	5	29	34	2.7	2.4	5.8	5.7	0	2	3	0	1	5	6	0.5	0.4				
d. Lymphoreticular	4	8	4	4	0	20	20	1.9	1.5	1.7	1.5	6	4	0	2	1	12	13	1.2	1.0				
e. Unspecified	0	10	8	10	13	28	41	2.5	2.8	1.3	1.6	2	5	4	11	4	22	26	2.0	1.8				
<b>III CNS NEOPLASMS †</b>	8	64	77	46	51	195	246	18.0	17.1	1.0	1.1	11	60	74	45	42	190	232	17.9	16.4				
a. Ependymoma	2	6	9	1	0	18	18	1.7	1.3	1.2	1.1	2	3	6	4	1	15	16	1.4	1.1				
b. Astrocytoma	0	23	30	17	29	70	99	6.4	6.7	0.9	1.0	3	20	36	17	23	76	99	7.1	6.9				
c. CNS embryonal	2	21	22	14	10	59	69	5.5	4.8	1.1	1.1	2	25	13	16	7	56	63	5.4	4.6				
d. Other gliomas	0	4	2	2	4	8	12	0.8	0.8	0.5	0.7	0	5	6	4	2	15	17	1.4	1.2				
e. Other specified	0	3	0	4	1	7	8	0.6	0.6	-	2.7	0	0	0	0	3	0	3	-	0.2				
f. Unspecified CNS	4	7	14	8	7	33	40	3.0	2.8	1.2	1.2	4	7	13	4	6	28	34	2.7	2.4				
<b>IV NEUROBLASTOMA</b>	5	9	3	1	1	18	19	1.8	1.5	0.8	0.8	3	7	4	9	2	23	25	2.2	1.8				
a. (Ganglio)neuroblastoma	5	9	3	1	1	18	19	1.8	1.5	0.9	0.9	2	7	4	8	1	21	22	2.0	1.6				
b. Peripheral nervous	0	0	0	0	0	0	0	-	-	0.0	0.0	1	0	0	1	1	2	3	0.2	0.2				
<b>V RETINOBLASTOMA</b>	14	58	6	0	0	78	78	8.2	6.3	1.4	1.4	14	41	2	0	0	57	57	6.2	4.8				
<b>VI RENAL TUMOURS</b>	9	46	10	1	3	66	69	6.8	5.4	1.1	1.1	5	34	18	4	1	61	62	6.2	4.8				
a. Nephroblastoma	7	45	10	1	1	63	64	6.5	5.1	1.1	1.2	4	31	16	4	0	55	55	5.6	4.3				
b. Renal carcinoma	0	0	0	0	1	0	1	-	0.1	-	1.0	0	0	0	0	1	0	1	-	0.1				
c. Unspecified	2	1	0	0	1	3	4	0.3	0.3	0.5	0.7	1	3	2	0	0	6	6	0.6	0.5				
<b>VII HEPATIC TUMOURS</b>	6	21	8	8	6	43	49	4.2	3.6	1.9	1.9	9	8	3	3	3	23	26	2.4	2.0				
a. Hepatoblastoma	6	17	5	4	1	32	33	3.2	2.5	1.9	1.8	8	6	2	1	1	17	18	1.8	1.4				
b. Hepatic carcinoma	0	0	2	4	3	6	9	0.5	0.6	6.0	3.0	0	0	0	1	2	1	3	0.1	0.2				
c. Unspecified	0	4	1	0	2	5	7	0.5	0.5	1.0	1.4	1	2	1	1	0	5	5	0.5	0.4				
<b>VIII BONE TUMOURS</b>	0	2	18	63	54	83	137	6.7	8.5	1.4	1.4	0	2	18	38	40	58	98	4.8	6.1				
a. Osteosarcoma	0	0	14	47	39	61	100	4.9	6.2	1.4	1.4	0	0	12	33	27	45	72	3.7	4.5				
b. Chondrosarcoma	0	0	2	2	0	4	4	0.3	0.3	2.0	1.3	0	0	1	1	1	2	3	0.2	0.2				
c. Ewing & related	0	2	2	8	9	12	21	1.0	1.3	1.5	1.5	0	2	4	2	6	8	14	0.7	0.9				
d. Other specified	0	0	0	1	2	1	3	0.1	0.2	1.0	0.8	0	0	0	1	3	1	4	0.1	0.2				
e. Unspecified	0	0	0	5	4	5	9	0.4	0.6	2.5	1.8	0	0	1	1	3	2	5	0.2	0.3				
<b>IX SOFT TISSUE SARCOMA</b>	8	17	21	24	39	70	109	6.4	7.3	1.1	1.2	6	17	9	32	27	64	91	5.8	6.2				
a. Rhabdomyosarcoma	4	10	12	8	11	34	45	3.2	3.1	1.0	1.1	3	10	4	18	7	35	42	3.2	2.9				
b. Fibrosarcoma	2	2	2	3	9	9	18	0.8	1.2	1.5	1.8	1	2	1	2	4	6	10	0.6	0.7				
c. Kaposi sarcoma	0	0	0	0	1	0	1	-	0.1	0.0	1.0	0	0	0	1	0	1	1	0.1	0.1				
d. Other specified	1	3	5	9	12	18	30	1.6	2.0	1.5	1.4	1	3	2	6	10	12	22	1.1	1.4				
e. Unspecified	1	2	2	4	6	9	15	0.8	1.0	0.9	0.9	1	2	2	5	6	10	16	0.9	1.1				
<b>X GERM CELL TUMOURS</b>	12	32	6	6	93	56	149	5.7	10.2	1.0	1.1	1	5	15	35	77	56	133	4.8	8.3				
a. CNS germ cell	1	2	1	2	3	6	9	0.6	0.6	3.0	4.5	0	1	0	1	0	2	2	0.2	0.1				
b. Other extragonadal	2	2	2	1	5	7	12	0.7	0.8	1.4	0.9	0	3	0	2	8	5	13	0.5	0.9				
c. Gonadal germ cell	9	28	2	2	82	41	123	4.3	8.4	1.0	1.4	1	1	13	28	48	43	91	3.6	5.7				
d. Gonadal carcinoma	0	0	0	1	0	1	1	0.1	0.1	-	0.1	0	0	0	0	15	0	15	-	0.9				
e. Unspecified gonadal	0	0	1	0	3	1	4	0.1	0.3	0.2	0.3	0	0	2	4	6	6	12	0.5	0.7				
<b>XI CARCINOMA &amp; MELANOMA</b>	4	3	11	20	59	38	97	3.3	6.2	0.9	0.7	0	4	11	27	106	42	148	3.6	9.1				
a. Adrenocortical	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.1				
b. Thyroid	0	0	3	3	13	6	19	0.5	1.2	0.3	0.3	0	0	4	19	51	23	74	1.9	4.5				
c. Nasopharyngeal	0	0	0	0	1	0	1	-	0.1	-	-	0	0	0	0	0	0	0	-	-				
d. Melanoma	4	2	3	2	4	11	15	1.1	1.1	1.8	1.9	0	2	3	1	2	6	8	0.6	0.6				
e. Skin carcinoma	0	0	3	11	17	14	31	1.1	1.9	2.8	2.1	0	2	2	1	10	5	15	0.5	1.0				
f. Other & unspecified	0	1	2	4	24	7	31	0.6	1.9	0.9	0.6	0	0	2	6	42	8	50	0.7	3.0				
<b>XII OTHER &amp; UNSPECIFIED</b>	4	8	6	11	14	29	43	2.7	2.9	0.9	0.9	3	10	7	13	16	33	49	3.1	3.3				
a. Other specified	0	0	0	1	1	1	2	0.1	0.1	0.5	0.5	0	2	0	0	2	2	4	0.2	0.3				
b. Other unspecified	4	8	6	10	13	28	41	2.6	2.8	0.9	0.9	3	8	7	13	14	31	45	2.9	3.1				
<b>TOTAL</b>	101	622	491	427	620	1641	2261	152.9	157.0	1.2	1.2	105	470	401	401	507	1377	1884	130.2	131.4				

† includes 4 non-malignant in males and 1 non-malignant in females

Please consult the quality indicators for the constituent registries

## ECUADOR, 5 registries (1993-2013)

	Age group	Males	Females
Person-years	0	665 204	645 634
	1-4	2 980 373	2 901 610
	5-9	3 700 749	3 623 561
	10-14	3 715 906	3 671 713
	15-19	3 627 287	3 742 120
Total	0-14	11 062 232	10 842 518
	0-19	14 689 519	14 584 638
Average annual population	0-14	526 773	516 310
	0-19	699 501	694 507

Please consult the quality indicators for the constituent registries

## ECUADOR, 5 registries (1993-2013)

Registry	Period	Cases	%	Person-years	%
Cuenca	1996-2013	460	11.1	3 414 928	11.7
Guayaquil	2008-2012	758	18.3	4 469 368	15.3
Loja	1997-2013	226	5.5	1 403 326	4.8
Manabí	1995-2011	850	20.5	8 962 965	30.6
Quito	1993-2012	1851	44.7	11 023 570	37.7
<b>ECUADOR</b>	<b>1993-2013</b>	<b>4145</b>	<b>100.0</b>	<b>29 274 157</b>	<b>100.0</b>

Please consult the quality indicators for the constituent registries

International Incidence of Childhood Cancer Volume III <http://iicc.iarc.fr/results>

Loja  
(1997-2013)

	0-14			0-19		
	Cases	M/F	ASR	Cases	M/F	ASR
<b>I LEUKAEMIA</b>	83	1.5	82.4	100	1.4	74.5
a. Lymphoid	55	2.1	54.5	64	1.9	47.9
b. Acute myeloid	17	0.9	15.9	21	0.9	14.9
c. CMD	9	0.5	9.9	12	0.5	9.6
d. MDS & other	0	.	.	0	.	.
e. Unspecified	2	.	2.1	3	.	2.2
<b>II LYMPHOMA &amp; RELATED</b>	22	2.7	20.8	33	1.5	23.0
a. Hodgkin	6	.	5.3	9	2.0	6.0
b. Non-Hodgkin except BL	12	1.4	11.7	19	1.1	13.4
c. Burkitt (BL)	2	.	1.8	3	.	2.1
d. Lymphoreticular	1	.	1.2	1	.	0.9
e. Unspecified	1	0.0	0.8	1	0.0	0.6
<b>III CNS NEOPLASMS</b>	17	0.5	16.1	23	0.6	16.2
a. Ependymoma	3	0.0	3.1	3	0.0	2.4
b. Astrocytoma	8	0.6	7.5	12	0.5	8.3
c. CNS embryonal	4	1.0	3.7	5	1.5	3.5
d. Other gliomas	0	.	.	0	.	.
e. Other specified	1	.	0.8	1	.	0.6
f. Unspecified CNS	1	0.0	0.9	2	1.0	1.3
<b>IV NEUROBLASTOMA</b>	1	0.0	1.2	2	0.0	1.5
a. (Ganglio)neuroblastoma	1	0.0	1.2	2	0.0	1.5
b. Peripheral nervous	0	.	.	0	.	.
<b>V RETINOBLASTOMA</b>	7	2.5	8.1	7	2.5	6.3
<b>VI RENAL TUMOURS</b>	5	1.5	5.1	5	1.5	3.9
a. Nephroblastoma	5	1.5	5.1	5	1.5	3.9
b. Renal carcinoma	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.
<b>VII HEPATIC TUMOURS</b>	7	0.4	7.4	8	0.3	6.3
a. Hepatoblastoma	6	0.5	6.6	6	0.5	5.1
b. Hepatic carcinoma	0	.	.	1	0.0	0.6
c. Unspecified	1	0.0	0.8	1	0.0	0.6
<b>VIII BONE TUMOURS</b>	6	2.0	4.9	12	2.0	7.5
a. Osteosarcoma	6	2.0	4.9	11	1.8	6.9
b. Chondrosarcoma	0	.	.	0	.	.
c. Ewing & related	0	.	.	0	.	.
d. Other specified	0	.	.	0	.	.
e. Unspecified	0	.	.	1	.	0.6
<b>IX SOFT TISSUE SARCOMA</b>	6	2.0	6.0	8	3.0	5.9
a. Rhabdomyosarcoma	3	.	2.9	3	.	2.2
b. Fibrosarcoma	2	1.0	2.3	3	2.0	2.4
c. Kaposi sarcoma	0	.	.	0	.	.
d. Other specified	0	.	.	0	.	.
e. Unspecified	1	0.0	0.8	2	1.0	1.3
<b>X GERM CELL TUMOURS</b>	8	1.0	8.2	13	0.6	9.5
a. CNS germ cell	2	1.0	2.3	2	1.0	1.8
b. Other extragonadal	0	.	.	0	.	.
c. Gonadal germ cell	6	1.0	5.9	10	0.7	7.1
d. Gonadal carcinoma	0	.	.	0	.	.
e. Unspecified gonadal	0	.	.	1	0.0	0.6
<b>XI CARCINOMA &amp; MELANOMA</b>	5	0.7	4.2	12	0.7	7.6
a. Adrenocortical	0	.	.	0	.	.
b. Thyroid	3	0.0	2.4	8	0.3	5.0
c. Nasopharyngeal	0	.	.	0	.	.
d. Melanoma	0	.	.	0	.	.
e. Skin carcinoma	1	.	0.9	1	.	0.7
f. Other & unspecified	1	.	0.8	3	2.0	1.9
<b>XII OTHER &amp; UNSPECIFIED</b>	1	.	1.2	3	.	2.1
a. Other specified	0	.	.	0	.	.
b. Other unspecified	1	.	1.2	3	.	2.1
<b>TOTAL</b>	168	1.4	165.3	226	1.2	164.4

Please consult the quality indicators for the constituent registries